Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.

Thoracic cancer - 1 May 2022

Zhang Meng, Cheng Yuan, Hu Yan, Nie Ligong

Abstract excerpt

A therapeutic option for advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance is a clinical challenge. The clinical outcomes of pembrolizumab in those patients is inconclusive. Cytokine release syndrome (CRS) is a rarely reported immune-related adverse event in the field of immune checkpoint inhibitors therapy, raising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35384319
DOI: 10.1111/1759-7714.14390
PMCID: PMC9058301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.PMID 35384319Read ↗

Cytokine Release Syndrome–Compatible Fever After Initiation of Local Radiotherapy During Late-Phase Epcoritamab Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case ReportSemantic proximity Read ↗

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in SwedenSemantic proximity Read ↗

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read ↗

Management of adverse reactions to biologic agents.Semantic proximity Read ↗

Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype associationSemantic proximity Read ↗

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

Case Report: Fatal myocarditis after combination of immune checkpoint inhibitor and platinum doublet chemotherapySemantic proximity Read ↗

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

Trousseau's syndrome triggered by an immune checkpoint blockade in a non‐small cell lung cancer patientSemantic proximity Read ↗

Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.Semantic proximity Read ↗

Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.